

AA

03CO#3

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

57557-013

In Re Application Of: Nathan et al.

SEP 20 2001

Serial No.

09/865,966

Filing Date

5/25/01

Examiner

Unassigned

Group Art Unit

Unassigned

Title: Drug-Amino Acid Sequence Chimeric Molecules

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

57557-013

In Re Application Of: Nathan et al.

Serial No.
09/865,966Filing Date
5/25/01Examiner
UnassignedGroup Art Unit
Unassigned

Title: Drug-Amino Acid Sequence Chimeric Molecules

Payment of Fee



(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 50-0385 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$240.00
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.


Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____ (Date)
_____ Signature
_____ Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 9-10-01 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.
 Signature of Person Mailing Correspondence
 Typed or Printed Name of Person Mailing Correspondence

*This certificate may only be used if paying by deposit account.



Signature

Dated: September 10, 2001

James E. Eakin, Reg. No. 27,874

McDermott, Will & Emery
2700 Sand Hill Road
Menlo Park, CA 94025
Tel: (650) 233-5500

CC:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

SEP 20 2001

Docket Number (Optional)

57557-013

Application Number

09/865,966

Applicant(s)

Asher Nathan

Filing Date

5/25/01

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	5,843,701	12/1/98	Gold et al.			
	B	5,622,699	4/22/97	Ruoslahti et al.			
	C	5,773,598	6/30/98	Burke et al.			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO
	AA	WO 98/34110	8/6/98	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AAA	Poul, Maria-Alix et al., "Selection of Tumor-Specific Internalizing Human Antibodies from Phage Laboratories", Journal of Molecular Biology (JMB), 2000, 301, pp. 1149-1161

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.